CCM
TXG icon

Camber Capital Management’s 10x Genomics TXG Stock Holding History

Camber Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,000,000
Closed -$8.73M – 35
2025
Q1 		$8.73M Hold
1,000,000
– – 0.31% 28
2024
Q4 		$14.4M Buy
+1,000,000
New +$15.8M 0.33% 35

Other funds holding TXG

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Camber Capital Management's TXG Position: Q2 2025 in Review

Camber Capital Management sold out of 10x Genomics (TXG) in Q2 2025, closing a stake of 1,000,000 shares — an estimated $8.73M sold.

Camber Capital Management first reported a position in TXG in Q4 2024 and held it in 2 quarters. The position peaked at $14.4M in Q4 2024. 297 funds tracked by Wall St. Rank hold TXG as of Q2 2025.

  • Camber Capital Management reported no remaining 10x Genomics position as of Q2 2025 after selling out during the quarter.
  • Camber Capital Management sold 1,000,000 10x Genomics shares in Q2 2025, an estimated $8.73M.
  • Camber Capital Management first reported a position in 10x Genomics in Q4 2024 and held it in 2 quarters.
  • Camber Capital Management's 10x Genomics position peaked at $14.4M in Q4 2024.
  • 297 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.